Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Armando Lira Pineda"'
Autor:
Mikhail Zaslavskiy, Armando Lira Pineda, David Dellamonica, Adrien Rousset, Robert P. Giugliano, Marc S. Sabatine, Romuald Menuet, Paul Trichelair, L. Ricci
Publikováno v:
European Heart Journal - Digital Health. 3:38-48
Aims Through this proof of concept, we studied the potential added value of machine learning (ML) methods in building cardiovascular risk scores from structured data and the conditions under which they outperform linear statistical models. Methods an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edc544d6e87a812b559c90119d2213f7
https://doi.org/10.1093/ehjdh/ztab093
https://doi.org/10.1093/ehjdh/ztab093
Autor:
Chung-Wah Siu, Peter S. Sever, Robert P. Giugliano, John Amerena, Donghoon Choi, Armando Lira Pineda, Prakash Deedwania, Min-Ji Charng, Terje R. Pedersen, Anthony C Keech, Leslie Tay, Marc S. Sabatine, Vijay K. Chopra, Chen Lu, Kazuma Oyama, Atsushi Hirayama, Wan Azman Wan Ahmad, Sabina A. Murphy, Minao Tang
Publikováno v:
Circulation Journal. 85:2063-2070
BACKGROUND There are concerns that Asian patients respond differently to some medications. This study evaluated the efficacy and safety of evolocumab among Asian vs. other subjects in the FOURIER trial, which randomized stable atherosclerosis patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e61c486e407519eb32db92fc4d0c6cda
https://doi.org/10.1253/circj.cj-20-1051
https://doi.org/10.1253/circj.cj-20-1051
Autor:
Petr Jarolim, Marc S. Sabatine, Nicholas A Marston, Huei Wang, Anthony C Keech, David A. Morrow, Minao Tang, Kazuma Oyama, Robert P. Giugliano, Peter S. Sever, Armando Lira Pineda
Publikováno v:
Circulation. 144:249-251
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bf055573fd58d6ef7abace7ddcafd9e
https://doi.org/10.1161/circulationaha.121.054663
https://doi.org/10.1161/circulationaha.121.054663
Autor:
Marc S. Sabatine, Huei Wang, Terje R. Pedersen, Frederick K. Kamanu, Anthony C Keech, Yared Gurmu, Francesco Nordio, Nicholas A Marston, Steven A. Lubitz, Carolina Roselli, Christian T. Ruff, Robert P. Giugliano, Patrick T. Ellinor, Peter S. Sever, Armando Lira Pineda
Publikováno v:
Circulation
Circulation, 141(8), 616-623. LIPPINCOTT WILLIAMS & WILKINS
Circulation, 141(8), 616-623. LIPPINCOTT WILLIAMS & WILKINS
Background: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been established.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f8378591ab7953ca243556eb546e04e
https://research.rug.nl/en/publications/16493d87-1a00-4924-9cd8-d27605935d89
https://research.rug.nl/en/publications/16493d87-1a00-4924-9cd8-d27605935d89
Autor:
Philippe Gabriel Steg, Deepak L. Bhatt, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven Ketchum, Lixia Jiao, Armando Lira Pineda, Ralph T. Doyle, Jean Claude Tardif, Christie M. Ballantyne
Publikováno v:
Journal of the American College of Cardiology. 81:1113
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1227c0bc8616816115c45839c22a12a0
https://doi.org/10.1016/s0735-1097(23)01557-7
https://doi.org/10.1016/s0735-1097(23)01557-7
Autor:
Prakash Deedwania, David M. Charytan, Scott M. Wasserman, Terje R. Pedersen, Robert Giugliano, Anders G. Olsson, J-G Park, Sabatine, Anthony Keech, Peter S. Sever, Armando Lira Pineda
Publikováno v:
Journal of the American College of Cardiology. 74:1162-1166
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bd79d5f16f5026607a3ffa866cd32bd
https://doi.org/10.1016/j.jacc.2019.06.041
https://doi.org/10.1016/j.jacc.2019.06.041
Autor:
Nicholas A Marston, Seung Hoan Choi, Marc S. Sabatine, Anthony C Keech, Christian T. Ruff, Huei Wang, Patrick T. Ellinor, Frederick K. Kamanu, Robert P. Giugliano, Giorgio E. M. Melloni, Steven A. Lubitz, James P. Pirruccello, Peter S. Sever, Armando Lira Pineda, Anthony A. Philippakis
Publikováno v:
Circulation. 142
Introduction: Patients with loss of function (LoF) mutations of the LDL receptor gene (LDLR) have lifelong elevations in LDL-C. We investigated their risk of cardiovascular (CV) events compared with patients with intact LDLR function. Methods: We per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4a7d18db5dfa13687e88913dab5a41f
https://doi.org/10.1161/circ.142.suppl_3.13588
https://doi.org/10.1161/circ.142.suppl_3.13588
Autor:
Anthony C Keech, Marc S. Sabatine, Petr Jarolim, David A. Morrow, Robert P. Giugliano, Huei Wang, Minao Tang, Peter S. Sever, Armando Lira Pineda, Kazuma Oyama, Nicholas A Marston
Publikováno v:
Circulation. 142
Introduction: The 2018 AHA/ACC cholesterol guidelines only recommend PCSK9 inhibitors in patients with very high risk ASCVD. However, high-sensitivity troponin (hsTn) can reclassify some lower risk patients as very high risk, identifying a subgroup w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f441c63a47fe5ec8380c20fa3d2179c8
https://doi.org/10.1161/circ.142.suppl_3.13117
https://doi.org/10.1161/circ.142.suppl_3.13117
Autor:
Narimon Honarpour, Marc S. Sabatine, Anthony C Keech, Terje R. Pedersen, Sabina A. Murphy, Scott M. Wasserman, Jeffrey L. Saver, Peter S. Sever, Armando Lira Pineda, Robert P. Giugliano, Huei Wang, Erin A. Bohula
Publikováno v:
Stroke. 51(5)
Background and Purpose— The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5–1.2) mmol/L and significantly reduced major vascular events in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb9dc127232dab95ec42c887a4a9fd8c
https://pubmed.ncbi.nlm.nih.gov/32312221
https://pubmed.ncbi.nlm.nih.gov/32312221
Autor:
Gaetano M. De Ferrari, Basil S. Lewis, Prakash Deedwania, Stephen D. Wiviott, Lawrence A. Leiter, Terje R. Pedersen, Julia F Kuder, Narimon Honarpour, Robert P. Giugliano, Anthony C Keech, Sabina A. Murphy, Peter S. Sever, Armando Lira Pineda, Yehuda Handelsman, Ioanna Gouni-Berthold, Marc S. Sabatine
Publikováno v:
The Lancet Diabetes & Endocrinology. 5:941-950
Summary Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated the efficacy and safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::887f1a563ff2f7cfc941c45bc0db2aa9
https://doi.org/10.1016/s2213-8587(17)30313-3
https://doi.org/10.1016/s2213-8587(17)30313-3